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Abstract. Chronic lithium therapy in patients with affective psychiatric
disorders has been implicated as the cause of hypercalcemia and primary
hyperparathyroidism. Our objective was to evaluate whether primary hy-
perparathyroidism was caused by an adenoma or four-gland hyperplasia.
The medical records of 15 patients with affective psychiatric disorders who
were treated with chronic lithium therapy from 1982 to 1997, all of whom
were operated on for primary hyperparathyroidism, were reviewed. Data
on age, symptoms, duration of lithium therapy, pre- and postoperative cal-
cium levels, and parathyroid hormone levels were collected. Parathyroid
histology for each patient was independently and blindly reviewed. The
mean age was 58 ± 10 years, the mean duration of lithium therapy 10.7 ±
6 years, and the mean preoperative calcium level 11.7 ± 0.5 mg/dl. All pa-
tients underwent bilateral neck exploration with selective resection of en-
larged glands. Of the 15 patients, 14 (92%) had adenomas (11 single, 3
double), and 1 (8%) had four-gland hyperplasia. All patients were rendered
eucalcemic, with a postoperative calcium level of 9.2 ± 0.5 mg/dl (p <
0.005). All patients resumed their lithium therapy, with 1 of 15 patients
developing recurrent hyperparathyroidism 2 years following the first op-
eration; this patient required reexploration, at which time an adenoma was
resected. In our experience hyperparathyroidism in patients who have un-
dergone prolonged therapy with lithium is associated with a high incidence
of parathyroid adenomas versus four-gland hyperplasia. This suggests that
lithium selectively stimulates growth of parathyroid adenomas in suscep-
tible patients, who are best treated with adenoma excision rather than sub-
total parathyroidectomy.
Lithium therapy has proven to be highly effective for bipolar illness
since its introduction in 1949. Garfinkel et al. were the first to sug-
gest an association between prolonged lithium therapy and the de-
velopment of hyperparathyroidism [1]. Since 1973 about 50 cases
have been reported, suggesting enhanced occurrence of hyperpara-
thyroidism in patients with affective psychiatric disorders treated
by lithium [2]. Approximately 10% to 15% of lithium-treated pa-
tients become hypercalcemic, with laboratory evidence and symp-
toms of hyperparathyroidism. In these patients it remains unclear
whether lithium initiates the disease or promotes underlying hyper-
parathyroidism. Previous studies have reported conflicting results
that prolonged lithium therapy causes four-gland hyperplasia, and
others report adenomas. We sought to review the cause of primary
hyperparathyroidism in our population of patients with affective
psychiatric disorders who had undergone treatment with prolonged
lithium therapy.
Patients and Methods
The medical records of patients with a diagnosis of bipolar disorder
who were treated with chronic lithium therapy and operated on for
primary hyperparathyroidism from 1982 to 1997 were reviewed.
During the study period 400 patients were identified with bipolar
disorder, 348 of whom were on chronic lithium therapy. Of these
patients, 15 were identified with hypercalcemia and underwent ex-
ploration (study group). The incidence of hyperparathyroidism in
this cohort of patients is 4.3%, which is higher than the 1% inci-
dence reported for the normal population.
For each patient, age, symptoms (fatigue, bone pain, renal cal-
culi, constipation), duration of lithium therapy, pre- and postopera-
tive calcium levels, parathyroid hormone (PTH) levels, and loca-
tion of their enlarged gland(s) were collected. Routine bilateral
neck exploration was performed with the aim of identifying all four
parathyroid glands. Enlarged glands were resected; and in the case
of four-gland enlargement, a 3.5-gland resection was performed.
Resected glands were sent to the pathology department to be
weighed and permanent sections prepared for histologic diagnosis.
The parathyroid histology for each patient was independently
reviewed and confirmed. The distinction between adenoma and hy-
perplasia was based on the combination of gross features and his-
tologic parameters. A diagnosis of adenoma was made if micro-
scopic examination revealed cohesive sheets of cells partly
surrounded by a rim of normal glandular tissue with absent or scant
adipose tissue [3]. In contrast, parathyroid hyperplasia was diag-
nosed if the resected gland was composed of mixed cellularity with
stromal fat cells and scant normal glandular tissue present [3].
Data are presented as means ± SEM. Univariate comparisons
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were made using the unpaired Student’s t-test. A value of p < 0.05
was significant. Correlation between groups was tested using the
Spearman rank test.
Results
Altogether, 15 patients on chronic lithium therapy for affective psy-
chiatric disorders developed symptomatic hyperparathyroidism
during the study period and underwent bilateral neck exploration.
The demographic data, duration of therapy with lithium, daily dose
of lithium, and parathyroid histology are shown in Table 1. The
mean age was 58 ± 10 years; the mean duration of lithium therapy
was 10.7 ± 6 years; and the mean preoperative calcium level was
11.7 ± 0.5 mg/dl. The patient’s symptoms are shown in Table 2.
Symptoms included fatigue, constipation, bone pain, bone frac-
tures, and renal stones. All patients underwent bilateral neck ex-
ploration with selective resection of enlarged glands.
Histological review revealed adenomas in 92% of patients (14/
15; single 11, double 3). Of the 15 patients, 1 (8%) had four-gland
hyperplasia and underwent 3.5-gland resection. All patients were
rendered eucalcemic with a postoperative calcium level of 9.2 ± 0.5
mg/dl (p < 0.005, compared to preoperative levels). All patients
resumed their lithium therapy with improvement in their nonpsy-
chiatric symptoms of hyperparathyroidism. Of the 15 patients, 1
developed recurrent hyperparathyroidism 2 years following the ini-
tial operation, having resumed lithium therapy for his bipolar dis-
ease (follow-up 2–17 years). The patient required neck reex-
ploration, and an adenoma was resected; the other two glands
appeared normal. There was poor correlation between the dura-
tion of lithium therapy and the histology (adenoma or hyperplasia)
(R = 0.16). Also there was poor correlation between the duration
of lithium therapy and preoperative calcium levels (R = 0.33).
Discussion
Lithium-induced hyperparathyroidism is relatively uncommon and
has been reported in only 49 patients to date [4–11]. Altogether, 33
patients had parathyroid adenomas, and 16 had parathyroid hyper-
plasia. Calcium levels of patients on chronic lithium therapy have
been shown to be elevated in 15% to 20% and may be a direct effect
of lithium on PTH secretion [12, 13]. In most patients lithium-
induced hyperparathyroidism is reversible when lithium is with-
drawn, but for many patients continued therapy is a necessity.
To date, the evidence is inconclusive as to whether chronic
stimulation with lithium has a provoking versus a causal role in the
development of hyperparathyroidism. In vitro, in bovine parathy-
roid cells it has been shown that lithium blunts the normal cytosolic
calcium response and augments the normal PTH secretory re-
sponse to changes in extracellular calcium [14, 15]. In vivo studies
show that lithium directly stimulates PTH secretion [16, 17]. It also
affects calcium metabolism at the renal level and accelerates loss of
bone density [10, 11].
It seems intuitive that the above-mentioned alterations should
cause hyperplastic changes, rather than adenoma formation, as all
four parathyroid glands are exposed to high serum levels of lithium.
It has been proposed that lithium stimulates the entire parathyroid
mass, resulting in hyperplasia [18]. A threefold increase in parathy-
roid volume has been documented by ultrasonography in patients
treated with lithium for a median of 8 years [19]. The literature does
not support this supposition, with 16 of 49 reported cases showing
parathyroid hyperplasia as the cause of hyperparathyroidism.
Moreover, the mean duration of therapy in our study group was
more than 10 years, with only one patient having parathyroid hy-
perplasia.
Alternatively, it has been suggested that chronic therapy with
lithium may unmask preexisting primary hyperparathyroidism by
serving as a mitogen promoting adenoma formation or by acceler-
ating growth in preexisting abnormal parathyroid tissue [16, 19].
Data from recent studies show an increase in DNA synthesis in cells
from parathyroid adenomas that was greater than that for cells
from hyperplastic parathyroid glands; there was no growth in nor-
mal cells [19–21]. This possibility is supported by the fact that para-
thyroid adenomas have been reported more often than hyperplasia
Table 1. Variables in patients treated with lithium for affective psychiatric disorders who developed primary hyperparathyroidism.




Li++ (mg) Parathyroid pathology
Location of
enlarged gland(s)
1 F 66 11 900 Single adenoma RS
2 F 57 21 600 Single adenoma LI
3 F 74 24 300 Single adenoma LS
4 F 59 7 300 Single adenoma RI, IT
5 F 61 12 600 Single adenoma LI
6 F 56 10 900 Single adenoma RS
7 M 60 3 600 Single adenoma RI
8 M 47 10 1600 Single adenoma LI
9 F 58 7 450 Double adenoma LS, LI
10 F 66 2 1200 Double adenoma RI, LI
11 M 34 11 600 Four-gland hyperplasia All
12 F 61 10 900 Double adenoma RS, LI
13 F 58 12 300 Single adenoma LI
14 F 51 5 600 Single adenoma RI
15 M 63 9 900 Single adenoma RI
RS: right superior; RI: right inferior; LS: left superior; LI: left inferior; IT: intrathyroidal; Li++: lithium.






Abdominal pain 1 6.7
Bone pain 2 13.3
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in patients on long-term lithium therapy (33 of 49 reported cases).
Our findings that most patients (92%) had parathyroid adenomas
corroborate this hypothesis. Additionally, in our report, the dura-
tion of therapy did not correlate with the presence of hyperplasia or
an adenoma.
Many patients on chronic lithium therapy have symptoms of hy-
perparathyroidism, such as decreased energy, easy fatigability, con-
stipation, and renal stones, all of which were found in our patients.
For patients who require ongoing treatment with lithium, surgery is
indicated. Based on our findings, we advocate continued routine
bilateral neck exploration with inspection of all four glands. These
patients may not be optimal candidates for minimally invasive para-
thyroid resection because of the observed incidence of double ad-
enomas. Excision should be limited to evident disease.
Conclusions
Review of the pathology of patients on chronic lithium therapy who
developed symptomatic hyperparathyroidism revealed adenomas
to be the predominant cause of the hyperparathyroidism. This is
consistent with most of the cases previously reported.
Résumé. La prise de lithium à long cours chez le patient atteint de désordre
psychiatrique affectif peut être responsable d’hypercalcémie et
d’hyperparathyroïdie primitive (HPTp). Notre objectif a été d’évaluer si
l’HPTp était en rapport avec un adénome ou une hyperplasie des quatre
glandes. On a revu les dossiers médicaux de 15 patients atteints de troubles
psychiatriques traités au long cours par le lithium, tous opérés pour HPTp
entre 1982–1997. On a colligé les données en ce qui concerne l’âge, les
symptômes, la durée du traitement par le lithium, les taux de calcémie pré-
et postopératoires, ainsi que les taux de PTH. On a obtenu une histologie de
la parathyroïde pour chaque patient, qui a été revue de façon indépendante
et aveugle. L’âge moyen a été de 58 ± 10 ans. La durée moyenne de
thérapeutique par le lithium a été de 10.7 ± 6 ans. La calcémie
préopératoire moyenne a été de 11.7 ± 0.5 mg/dl. Tous les patients ont eu
une exploration bilatérale du cou avec une résection sélective de toute
glande augmentée de volume. Quatorze des quinze patients (92%) avaient
des adénomes (11 uniques, 3 doubles). Un des quinze patients (8%) avait
une hyperplasie des quatre glandes. Tous les patients étaient
eucalcémiques avec une calcémie postopératoire de 9.2 ± 0.5 (p < 0.005).
Tous les patients ont pu reprendre leur lithium et seulement un des 15
patients a développé une HPTp récidivante 6 ans après sa première
intervention et a nécessité une réexploration avec résection pour adénome.
Dans notre expérience, l’hyperparathyroïdie chez les patients ayant eu un
traitement prolongé par le lithium est associée à une incidence élevée
d’adénome par rapport à l’hyperplasie des quatre glandes. Ces résultats
suggèrent que le lithium stimule de façon sélective la croissance des
adénomes de la parathyroïde: ces patients sont mieux traités par excision
de leur adénome plutôt que par une parathyroïdectomie subtotale.
Resumen. La terapia crónica con el litio en pacientes con alteraciones
psiquiátricas afectivas ha sido inculpada como causa de hipercalcemia e
hiperparatiroidismo primario. Nuestro propósito fue evaluar si tal
hiperparatiroidismo primario fue causado por un adenoma o por
hiperplasia de cuatro glándulas. Se revisaron las historias de 15 pacientes
atendidos entre 1982 y 1997 que sufrían alteraciones psiquiátricas
afectivas y que recibieron terapia crónica con litio y que fueron sometidos a
operación por hiperparatiroidismo primario. Se efectuó el registro de la
edad, los síntomas, la duración de la terapia con litio, los niveles pre y
postoperatorios de calcio y los niveles de parathormona, y se hizo la
revisión ciega e independiente de la histología paratiroidea. La edad
promedio fue 58 ± 10 años. El promedio de la duración de la terapia con
litio fue 10.7 ± 6 años. El nivel promedio del calcio sérico fue 11.7 ± 0.5
mg/dl. Se realizó exploración cervical bilateral en la totalidad de los
pacientes, con resección selectiva de las glándulas de tamaño aumentado.
Catorce de 15 pacientes (92%) presentaron adenomas (11 únicos, 3 dobles),
y sólo 1 (8%) presentó hiperplasia de cuatro glándulas. Todos los pacientes
convirtieron a eucalcemia, con un sodio sérico postoperatorio promedio de
9.2 ± 0.5 (p < 0.005). Todos reasumieron la terapia con litio y uno de los 15
desarrolló hiperparatiroidismo recurrente 6 años luego de la operación, lo
cual requirió reexploración y resección de un adenoma. En nuestra
experiencia, el hiperparatiroidismo en pacientes que reciben terapia
prolongada con litio se asocia con una elevada incidencia de adenomas
paratiroideos versus hiperplasia de cuatro glándulas, lo cual sugiere que el
litio puede estimular el crecimiento de adenomas paratiroideos en
pacientes susceptibles, quienes entonces deben ser tratados con resección
del adenoma en vez de paratiroidectomía subtotal.
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